MacroGenics (MGNX) Q3 2025 earnings summary

Executive summary

• Focused on developing antibody-based therapeutics for cancer, with three proprietary clinical candidates and multiple preclinical programs advancing.

• Strategic collaborations with global biopharma have provided over $1.6 billion in non-dilutive funding since inception.

• Secured $75 million in non-dilutive partnership payments from Sanofi and Gilead, expected in Q4 2025.

• Ended lorigerlimab development in prostate cancer based on interim data, but continued in ovarian and gynecologic cancers.

• Commercial-scale cGMP manufacturing facility supports clinical programs and contract manufacturing for third parties.

Financial highlights

• Total revenue for Q3 2025 was $72.8M, down 34% year-over-year; nine-month revenue was $108.3M, down 17%.

• Q3 2025 net income was $16.8M, compared to $56.3M in Q3 2024; nine-month net loss was $60.5M, compared to $51.5M loss in 2024.

• Cash, cash equivalents, and marketable securities totaled $146.4M at September 30, 2025, not including $75M in expected partner payments.

• R&D expenses decreased to $32.7M in Q3 2025 from $40.5M in Q3 2024.

• SG&A expenses fell to $9.9M in Q3 2025 from $14.1M in Q3 2024.

Outlook and guidance

• Cash runway projected into late 2027, supported by $50M receivable from Sanofi, partner payments, and cost-saving initiatives.

• Clinical update on the first part of the LINNET study expected by mid-2026.

• IND application for MGC030 planned for 2026.